iTeos Therapeutics (ITOS) News Today → Elon Musk’s Next Move Will Disrupt AI Forever (From InvestorPlace) (Ad) Free ITOS Stock Alerts $17.02 -0.42 (-2.41%) (As of 04:27 PM ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 13 at 10:45 AM | marketbeat.comiTeos Therapeutics (NASDAQ:ITOS) Sees Unusually-High Trading Volume After Analyst UpgradeiTeos Therapeutics (NASDAQ:ITOS) Sees Strong Trading Volume Following Analyst UpgradeMay 13 at 8:20 AM | marketbeat.comHC Wainwright Boosts iTeos Therapeutics (NASDAQ:ITOS) Price Target to $46.00HC Wainwright boosted their price objective on iTeos Therapeutics from $44.00 to $46.00 and gave the stock a "buy" rating in a research note on Monday.May 12 at 3:29 AM | americanbankingnews.comiTeos Therapeutics (NASDAQ:ITOS) Shares Gap Up to $12.19May 10 at 7:31 PM | marketwatch.comITeos Therapeutics Shares Surge 47% After Promising Tumor Treatment DataMay 10 at 9:07 AM | finanznachrichten.deiTeos Therapeutics Inc.: iTeos Reports First Quarter 2024 Financial Results and Provides Business UpdatesMay 10 at 9:07 AM | finanznachrichten.deiTeos Therapeutics Inc.: iTeos Therapeutics Announces $120 Million Registered Direct OfferingMay 10 at 8:26 AM | globenewswire.comiTeos Reports First Quarter 2024 Financial Results and Provides Business UpdatesMay 10 at 8:24 AM | globenewswire.comiTeos Therapeutics Announces $120 Million Registered Direct OfferingMay 6, 2024 | seekingalpha.comADC Therapeutics Non-GAAP EPS of -$0.38, revenue of $17.8M misses by $0.32MApril 16, 2024 | investing.comIteos Therapeutics Inc (ITOS)April 7, 2024 | globenewswire.comiTeos Presents EOS-984 Preclinical Data Demonstrating Restoration of T Cell Activity from Adenosine Suppression at the American Association for Cancer Research Annual Meeting 2024April 1, 2024 | marketbeat.comiTeos Therapeutics, Inc. (NASDAQ:ITOS) Sees Significant Increase in Short InterestiTeos Therapeutics, Inc. (NASDAQ:ITOS - Get Free Report) was the recipient of a large increase in short interest during the month of March. As of March 15th, there was short interest totalling 2,010,000 shares, an increase of 11.7% from the February 29th total of 1,800,000 shares. Based on an average daily trading volume, of 256,400 shares, the short-interest ratio is currently 7.8 days. Currently, 7.1% of the company's stock are sold short.March 22, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: iTeos Therapeutics (ITOS), Rani Therapeutics Holdings (RANI) and Vor Biopharma (VOR)March 19, 2024 | marketbeat.comCitigroup Inc. Sells 148,333 Shares of iTeos Therapeutics, Inc. (NASDAQ:ITOS)Citigroup Inc. cut its position in iTeos Therapeutics, Inc. (NASDAQ:ITOS - Free Report) by 63.2% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 86,334 shares of the company's stock after selling 148,333 shares during theMarch 18, 2024 | marketbeat.comiTeos Therapeutics, Inc. (NASDAQ:ITOS) Sees Large Growth in Short InterestiTeos Therapeutics, Inc. (NASDAQ:ITOS - Get Free Report) was the recipient of a significant increase in short interest in February. As of February 29th, there was short interest totalling 1,800,000 shares, an increase of 5.9% from the February 14th total of 1,700,000 shares. Based on an average trading volume of 301,800 shares, the days-to-cover ratio is presently 6.0 days. Approximately 6.3% of the shares of the stock are short sold.March 11, 2024 | finance.yahoo.comITOS Oct 2024 17.000 callMarch 11, 2024 | markets.businessinsider.comAnalysts Are Bullish on These Healthcare Stocks: iTeos Therapeutics (ITOS), Viracta Therapeutics (VIRX)March 11, 2024 | marketbeat.comiTeos Therapeutics, Inc. to Post Q1 2024 Earnings of ($1.22) Per Share, HC Wainwright Forecasts (NASDAQ:ITOS)iTeos Therapeutics, Inc. (NASDAQ:ITOS - Free Report) - Research analysts at HC Wainwright boosted their Q1 2024 earnings per share estimates for shares of iTeos Therapeutics in a research report issued to clients and investors on Thursday, March 7th. HC Wainwright analyst S. Ramakanth now expectsMarch 10, 2024 | finance.yahoo.comITOS Oct 2024 12.000 callMarch 10, 2024 | finance.yahoo.comITOS Mar 2024 4.000 putMarch 8, 2024 | marketbeat.comHC Wainwright Comments on iTeos Therapeutics, Inc.'s FY2027 Earnings (NASDAQ:ITOS)iTeos Therapeutics, Inc. (NASDAQ:ITOS - Free Report) - HC Wainwright decreased their FY2027 earnings per share (EPS) estimates for shares of iTeos Therapeutics in a research note issued to investors on Thursday, March 7th. HC Wainwright analyst S. Ramakanth now forecasts that the company will posMarch 7, 2024 | marketbeat.comiTeos Therapeutics (NASDAQ:ITOS) Posts Earnings Results, Beats Expectations By $0.18 EPSiTeos Therapeutics (NASDAQ:ITOS - Get Free Report) released its earnings results on Wednesday. The company reported ($0.85) EPS for the quarter, beating the consensus estimate of ($1.03) by $0.18.March 7, 2024 | marketbeat.comiTeos Therapeutics' (ITOS) Buy Rating Reaffirmed at HC WainwrightHC Wainwright reissued a "buy" rating and issued a $44.00 target price on shares of iTeos Therapeutics in a report on Thursday.March 6, 2024 | finanznachrichten.deiTeos Therapeutics Inc.: iTeos Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdatesMarch 6, 2024 | finance.yahoo.comITOS Mar 2024 11.000 callMarch 6, 2024 | marketbeat.comiTeos Therapeutics (NASDAQ:ITOS) Given "Outperform" Rating at WedbushWedbush reissued an "outperform" rating and set a $18.00 price target (down from $25.00) on shares of iTeos Therapeutics in a research report on Wednesday.March 6, 2024 | globenewswire.comiTeos Appoints Oncology Veteran Jill DeSimone to Its Board of DirectorsMarch 6, 2024 | globenewswire.comiTeos Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdatesMarch 5, 2024 | globenewswire.comiTeos to Highlight Preclinical Data on First-In-Class EOS-984 Targeting ENT1 at the American Association for Cancer Research Annual Meeting 2024March 1, 2024 | marketbeat.com683 Capital Management LLC Purchases 225,000 Shares of iTeos Therapeutics, Inc. (NASDAQ:ITOS)683 Capital Management LLC lifted its position in iTeos Therapeutics, Inc. (NASDAQ:ITOS - Free Report) by 38.5% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 810,000 shares of theMarch 1, 2024 | globenewswire.comiTeos to Participate in Upcoming Investor ConferencesFebruary 28, 2024 | marketbeat.comDeerfield Management Company L.P. Series C Makes New Investment in iTeos Therapeutics, Inc. (NASDAQ:ITOS)Deerfield Management Company L.P. Series C purchased a new stake in iTeos Therapeutics, Inc. (NASDAQ:ITOS - Free Report) in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor purchased 723,000 shares of theFebruary 16, 2024 | marketbeat.comiTeos Therapeutics, Inc. (NASDAQ:ITOS) Sees Significant Growth in Short InterestiTeos Therapeutics, Inc. (NASDAQ:ITOS - Get Free Report) was the recipient of a significant growth in short interest during the month of January. As of January 31st, there was short interest totalling 1,730,000 shares, a growth of 16.1% from the January 15th total of 1,490,000 shares. Based on an average trading volume of 302,100 shares, the days-to-cover ratio is presently 5.7 days. Currently, 6.1% of the company's shares are short sold.January 8, 2024 | marketbeat.comiTeos Therapeutics (NASDAQ:ITOS) Receives Outperform Rating from WedbushWedbush restated an "outperform" rating and set a $33.00 target price on shares of iTeos Therapeutics in a report on Monday.January 3, 2024 | finance.yahoo.comiTeos to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceJanuary 1, 2024 | marketbeat.comShort Interest in iTeos Therapeutics, Inc. (NASDAQ:ITOS) Expands By 17.3%iTeos Therapeutics, Inc. (NASDAQ:ITOS - Get Free Report) was the target of a large increase in short interest in December. As of December 15th, there was short interest totalling 2,030,000 shares, an increase of 17.3% from the November 30th total of 1,730,000 shares. Based on an average trading volume of 476,000 shares, the short-interest ratio is presently 4.3 days. Approximately 7.1% of the shares of the company are short sold.December 13, 2023 | finance.yahoo.comWall Street Analysts Believe iTeos Therapeutics, Inc. (ITOS) Could Rally 243.43%: Here's is How to TradeNovember 29, 2023 | fool.comiTeos Therapeutics (NASDAQ: ITOS)November 27, 2023 | finance.yahoo.comDoes iTeos Therapeutics, Inc. (ITOS) Have the Potential to Rally 283.59% as Wall Street Analysts Expect?November 21, 2023 | finance.yahoo.comiTeos to Present at the Piper Sandler 35th Annual Healthcare ConferenceNovember 14, 2023 | markets.businessinsider.comiTeos Therapeutics’ Anticipated Growth and Clinical Updates Drive Buy Rating: An Analyst’s PerspectiveNovember 13, 2023 | finance.yahoo.comHere's Why iTeos Therapeutics, Inc. (ITOS) Could be Great Choice for a Bottom FisherNovember 10, 2023 | finance.yahoo.comWall Street Analysts Predict a 304.26% Upside in iTeos Therapeutics, Inc. (ITOS): Here's What You Should KnowNovember 10, 2023 | finance.yahoo.comWall Street Analysts Predict a 304.26% Upside in iTeos Therapeutics, Inc. (ITOS): Here's What You Should KnowNovember 9, 2023 | markets.businessinsider.comPositive Financial Results and Promising Cancer Treatment Programs Underpin Buy Rating for iTeos TherapeuticsNovember 7, 2023 | finance.yahoo.comiTeos Reports Third Quarter 2023 Financial Results and Provides Business UpdatesOctober 31, 2023 | finance.yahoo.comViridian Therapeutics, Inc. (VRDN) Stock Jumps 5.2%: Will It Continue to Soar?October 19, 2023 | msn.comWedbush Reiterates ITeos Therapeutics (ITOS) Outperform RecommendationOctober 16, 2023 | finance.yahoo.comiTeos Therapeutics, Inc. (ITOS) Stock Jumps 5.4%: Will It Continue to Soar?October 12, 2023 | finanznachrichten.deS&P Dow Jones Indices: NCR Atleos Set to Join S&P SmallCap 600 Get iTeos Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ITOS and its competitors with MarketBeat's FREE daily newsletter. Email Address Millionaire investor and Republican donor makes surprising election prediction (Ad)Find out who Louis believes is going to win the election... And why that will launch a second boom in AI stocks Click for his six specific AI stock in the crosshairs ITOS Media Mentions By Week ITOS Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ITOS News Sentiment▼0.330.58▲Average Medical News Sentiment ITOS News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ITOS Articles This Week▼121▲ITOS Articles Average Week Get iTeos Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ITOS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: LXEO News Today FATE News Today ALVO News Today ADPT News Today REPL News Today TSHA News Today EDIT News Today CCCC News Today TCRX News Today VYGR News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ITOS) was last updated on 5/13/2024 by MarketBeat.com Staff From Our PartnersThe Department of Defense Has a New Drone ContractorThe Tomorrow InvestorHe Is Giving Away BitcoinCrypto Swap ProfitsObama’s Forever Term [exposed]Porter & CompanyThe A.I. story nobody is telling you (Read ASAP)TradeSmithForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressUrgent Nvidia WarningAltimetryThe Crypto 9-5 Escape PlanCrypto 101 MediaElon’s New Device is About to Shock the WorldInvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding iTeos Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
